1. Claudia Ortiz Lopez, PharmD Candidate Cone Health Family Medicine
News You Can Use…
Claudia Ortiz Lopez, PharmD Candidate
Kelsy Combs, PharmD
Pete Koval, PharmD
Cone Health Family Medicine
January, 2017

2. Brand-to-Generic Switch
Tamiflu® is now available generically as oseltamivir phosphate
Generic approved on 8/5/16, now available from Alvogen

3. Health Care Costs
US Spending on Personal Health care and Public Health
Highest Health Care Annual Spending
Diabetes $101.4 billion
Ischemic Heart Disease $88.1 billion
Low Back and Neck Pain $87.6 billion
JAMA. 2016;316(24):

4. FDA Approval MACI (Matrix-induced autologous chondrocyte implantation)
First FDA-approved product that uses tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee
For the repair of symptomatic, full thickness cartilage defects of the knee in adult patients
ADEs: joint pain, cold-like symptoms, headache, back pain

5. Statins in Younger Patients
New study showed low rates of statin prescription in younger patients with severe dyslipidemia (LDL >190 mg/dL)
Statins prescribed per age group:
30-40 yo – 32%
40-50 yo – 47%
50-60 yo – 61%
Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia. JAMA Cardiol. Published online January 04, 2017.

6. FDA Labeling Addition Jardiance ® (empagliflozin) MOA: SGLT2
FDA adds new indication to reduce the risk of CV death in adult patients with type 2 diabetes and CV disease

7. ADA 2017 update for Diabetes
Recommendation added to consider empagliflozin (SGLT2) or liraglutide (GLP1)
Median cost of noninsulin and insulin agents added
Noninferiority of GLP1 vs rapid acting insulin vs twice daily premixed insulin in addition to basal insulin
Diabetes Care 2017;40(Suppl. 1):S4–S5
Diabetes Care 2017;40(Suppl. 1):S64–S74

8. FDA Approval Spinraza® (nusinersen)
Class: survival motor neuron-2 (SMN2) directed antisense oligonucleotide
For the treatment of spinal muscular atrophy in pediatric and adult pateints
Dose: 12 mg intrathecally x 4 loading doses then every 4 months
ADE: respiratory infection, constipation

9. FDA Approval Eucrisa® (crisaborole)
Class: phosphodiesterase 4 (PDE-4) inhibitor
For the treatment of mild to moderate eczema (atopic dermatitis) in patients ≥ 2 yo
Dose: apply a thin layer of ointment twice daily
ADE: application site pain, hypersensitivity reaction